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• Capturing epidemiological and treatment data on rare conditions 
is challenging and this can be compounded by geographic 
dispersion of the relatively small numbers of patients.1
 –  The establishment of registries is a critical component of 
advancing rare disease research.1
• Atypical haemolytic uraemic syndrome (aHUS) is a rare 
genetic disease that affects both children and adults.2-5 It is a 
progressive, life-threatening condition that results from chronic, 
uncontrolled complement activation in most patients.3-5
 –  It is characterised by systemic thrombotic microangiopathy 
(TMA) leading to severe renal and other end-organ 
damage.3-5
• Plasma exchange and infusion (PE/PI) has been the treatment of 
choice for aHUS;3 however, evidence suggests that PE/PI only 
transiently maintains normal levels of hematologic markers and 
does not treat the underlying condition.4
• Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, 
CT, USA) is a terminal complement inhibitor,6 and the first 
approved treatment for aHUS in paediatric and adult patients.6-7
• The Global aHUS Patient Registry (NCT01522183) was initiated 
following approval of eculizumab at the request of the European 
and US regulatory authorities.
 –  The registry was implemented in April 2012 and 
prospectively captures effectiveness and safety data on 
patients treated with eculizumab.
 –  The registry records information on the progression 
of disease in all aHUS patients (whether treated with 
eculizumab or with other disease-management strategies).
• To report the characteristics of patients enrolled in the aHUS 
registry from its inception (April 2012) through to September 2013.
Patient Recruitment
• Between inception and 09 April 2014, 441 patients from  
14 countries worldwide were enrolled in the Global aHUS  
Patient Registry.
• In Europe, 295 (66.9%) patients were recruited from  
10 countries (Figure 1).
• Outside of Europe, 100 (22.7%), 26 (5.9%), 16 (3.6%) and 4 (0.9%) 
patients were enrolled in the USA, Australia, Israel and Canada, 
respectively.
Characteristics of Enrolled Patients
• Tables 1–4 provide information on demographics, aHUS 
diagnosis, baseline clinical characteristics and eculizumab 
treatment characteristics for the 211 patients enrolled at last 
data cutoff (18 September 2013).
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INTRODUCTION
OBJECTIVE
Patient Eligibility Criteria
• Male or female patients of any age with a clinical diagnosis of 
aHUS.
 –  With or without an identified complement regulatory factor 
genetic abnormality or anticomplement factor antibody (if 
tested).
 –  ADAMTS13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) >5%, if performed.
• Patients were excluded if they had haemolytic uraemic 
syndrome due only to Shiga toxin-producing Escherichia coli.
• All patients (or legal guardians) provided written informed 
consent to take part.
Primary Outcome Measures Collected
• Proportion of patients who experience specified events and time 
to first and subsequent occurrence of specified events.
• Long-term manifestations of TMA complications of aHUS.
• Safety and efficacy of eculizumab.
• Other clinical outcomes, including morbidity and mortality in 
patients receiving eculizumab or managed differently.
Data Collection
• The following data are collected at study enrolment and every 6 
months thereafter:
 – Demographics
 – Medical and disease history
 – Symptomatology
 –  Targeted laboratory results (including genetic results)
 – TMA complications
 –  Associated treatments and concomitant medications
 – Clinical and patient-reported outcomes
 –  Safety of eculizumab and other aHUS treatments.
• Each patient will be followed for a minimum of 5 years; data are 
stored anonymously.
Registry Support
• The registry is supported by Alexion Pharmaceuticals, Inc., with 
governance by an independent scientific advisory board and 
national coordinators representing each participating country.
METHODS
RESULTS
• The Global aHUS Patient Registry will contribute towards increasing the understanding and awareness of aHUS disease history  
and progression.
• Data collected via the registry will also improve knowledge of the safety and efficacy of eculizumab in aHUS.
• As of 18 September 2013, 211 patients were enrolled
 – Mean age at diagnosis was 21 years
 – Family history of aHUS was reported by 36 (17%) patients
 – Of those screened, 59% had an identified complement mutation
 – 34 (16.1%) patients had previously received a renal transplant.
• In April 2014, 441 patients had been enrolled.
• Results of analyses from collected data will ultimately provide the opportunity to optimise care and improve quality of life for patients with aHUS.
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Figure 1. European Distribution of Patient Enrolment April 2014
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Table 1. Patient Demographics
Ever treated with  
eculizumab (n=104)
Never treated with  
eculizumab (n=107)
Total
(N=211)
Mean age at registry enrolment (SD), years
n=100
24.9 (21.0)
n=98
25.0 (17.2)
n=198
25.0 (19.2)
Age at registry enrolment, n (%)
   <2 years
   ≥2 to <5 years
   ≥5 to <12 years
   ≥12 to <18 years
   ≥18 years
   N/A
17 (16.3)
8 (7.7)
15 (14.4)
5 (4.8)
55 (52.9)
4 (3.8)
2 (1.9)
7 (6.5)
18 (16.8)
16 (15.0)
55 (51.4)
9 (8.4)
19 (9.0)
15 (7.1)
33 (15.6)
21 (10.0)
110 (52.1)
13 (6.2)
Sex, n (%)
   Female
   Male
   N/A
58 (55.8)
46 (44.2)
0
45 (42.1)
54 (50.5)
8 (7.5)
103 (48.8)
100 (47.4)
8 (3.8)
N/A, not available; SD, standard deviation
Table 2. aHUS Diagnosis Characteristics
Ever treated with  
eculizumab (n=104)
Never treated with  
eculizumab (n=107)
Total
(N=211)
Mean age at initial symptoms (SD), years n=93
23.8 (21.4)
n=76
17.1 (16.4)
n=169
20.8 (19.5)
Mean age at diagnosis (SD), years n=94
23.9 (21.4)
n=75
17.1 (16.8)
n=169
20.9 (19.8)
Stated family history of aHUS
   Yes
   No
16 (15.4)
88 (84.6)
20 (18.7)
87 (81.3)
36 (17.1)
175 (82.9)
Any identified complement genetic mutation or 
autoantibody, or CFHR1/3 deletion, 
n/N screened (%)
   Yes
   No
47/88 (53.4)
41/88 (46.6)
45/69 (65.2)
24/69 (34.8)
92/157 (58.6)
65/157 (41.4)
N/A, not available; SD, standard deviation
Table 3. Baseline Clinical Characteristics
Ever treated with  
eculizumab (n=104)
Never treated with  
eculizumab (n=107)
Total
(N=211)
Management history prior to enrolment, n (%)
   Kidney transplant
   Dialysis
   Plasma exchange/infusion
14 (13.5)
58 (55.8)
59 (56.7)
20 (18.7)
33 (30.8)
31 (29.0)
34 (16.1)
91 (43.1)
90 (42.7)
Mean baseline eGFR (SD), mL/min/1.73 m2 n=39
42.8 (48.1)
n=29
76.0 (63.8)
n=68
57.0 (57.3)
SD, standard deviation
Table 4. Characteristics of Patients Treated with Eculizumab
Ever treated with eculizumab (n=103)
Mean age at eculizumab treatment initation (SD), years n=99
24.9 (21.1)
Mean time on eculizumab (SD), years n=100
1.2 (0.89)
Any discontinuation of eculizumab, n (%)
   No 
   Yes
 
86 (83.5)
17 (16.5)
Restarted eculizumab (among those who discontinued), n (%)
   No
   Yes
14 (82.4)
3 (17.6)
SD, standard deviation
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